What's happened
Cellmid Ltd ("Cellmid") has received notice of allowance for its Improved midkine antibody patent from the United States Patent and Trademark Office (USPTO). Further to this, the European Patent Office (EPO) has also now issued a ‘Decision to Grant’ following a ‘Notification of Intention to Grant’ in 2019.
Why is this significant?
These midkine antibody patents are expected to help Cellmid in attracting potential commercial partners. Cellmid now have a dominant intellectual property position over the use of midkine therapeutic antibodies for the treatment of diseases arising from cancer, chronic inflammation, as well as functional disorders in T-regulatory cells and activated neutrophils associated with autoimmune diseases.
